Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia

ClinicalTrials.gov ID: NCT01396421

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01396421. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Three Fixed Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to compare the effectiveness, safety and tolerability of three different doses of OPC-34712 with placebo in the treatment of acute schizophrenia in adults.

Study identification

NCT ID: NCT01396421
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Enrollment: 636 participants

Conditions and interventions

Conditions

Acute Schizophrenia

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 2011 (Type not available)
Primary completion: Jan 2014 (Actual)
Completion: Jan 2014 (Actual)
Last update posted: Oct 29, 2015

2011 – 2014

United States locations

U.S. sites: 17
U.S. states: 8
U.S. cities: 15

Facility	City	State	ZIP	Site status
Not listed	Little Rock	Arkansas	72205	—
Not listed	Garden Grove	California	92845	—
Not listed	Glendale	California	91206	—
Not listed	Oakland	California	94612	—
Not listed	Oceanside	California	92056	—
Not listed	San Diego	California	92102	—
Not listed	San Diego	California	92123	—
Not listed	Bradenton	Florida	34208	—
Not listed	Miami Springs	Florida	33166	—
Not listed	Orlando	Florida	32806	—
Not listed	Fresh Meadows	New York	11423	—
Not listed	Jamaica	New York	11432	—
Not listed	Dayton	Ohio	45417	—
Not listed	Charleston	South Carolina	29405	—
Not listed	Charleston	South Carolina	29407	—
Not listed	Austin	Texas	78754	—
Not listed	Kirkland	Washington	98033	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 43 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01396421, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 29, 2015 · Synced Nov 15, 2026